Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection

Documenti analoghi

• Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
  di: Navalkele, Bhagyashri D, et al.
  Pubblicazione: (2018)
• Bezlotoxumab for Clostridium difficile
  Pubblicazione: (2018)
• Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab
  di: Yang, Zhiyong, et al.
  Pubblicazione: (2015)
• The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection
  di: Džunková, Mária, et al.
  Pubblicazione: (2016)
• Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection
  di: Yee, Ka Lai, et al.
  Pubblicazione: (2019)